Cascadian Therapeutics, Inc. Watch

from 10-K 71 pages 3101 Western Avenue Seattle, Washington Sublease by and Between Cti Biopharma, Corp., a Washington Corporation as Sublandlord and Cascadian Therapeutics, Inc., a Delaware Corporation as Subtenant

from 10-K 4 pages Lease Termination Agreement [Fourth and Vine]

from 8-K 4 pages Transaction Bonus Agreement

from 8-K 1 page Form of Amendment to Executive Employment Agreement

from 8-K 1 page Amendment to Offer Letter of Employment

from 8-K 1 page Form of Amendment to Employee Confidentiality, Invention Assignment and Non-Compete Agreement

from 8-K 2 pages Amendment to Employee Invention Assignment and Confidentiality Agreement

from 8-K 22 pages Registration Rights Agreement

from 10-Q 10 pages 2016 Equity Incentive Plan Notice of Restricted Stock Unit Award

from 10-Q 10 pages 2016 Equity Incentive Plan Notice of Restricted Stock Unit Award

from 10-Q 11 pages 2016 Equity Incentive Plan Notice of Stock Option Grant

from 8-K 6 pages Subscription Agreement

from 8-K 19 pages Executive Employment Agreement

from 10-Q 8 pages Mutual Termination Agreement Between STC.UNM and Oncothyreon Inc

from 8-K 4 pages Release You Are Advised to Consult With an Attorney Before Signing This Release of Claims

from 8-K 4 pages April 1, 2016 Diana F. Hausman, M.D. C/O Oncothyreon Inc. 2601 Fourth Ave., Suite 500 Seattle, Wa 98121 Re: Resignation From Oncothyreon Inc. Dear Diana: This Letter Agreement States the Understanding and Agreement Between You and Oncothyreon Inc. (The “Company”) With Respect to Your Resignation From the Company. the Agreement Between You and the Company Is as Follows: 1. Resignation. You Voluntarily Resign From the Company Effective April 1, 2016 (The “Separation Date”). 2. Severance Obligations. (A) Accrued Obligations. the Company Will Pay You (I) Earned Salary, (II) Any Accrued but Unused Vacation, and (III) Reimbursement of Any Outstanding Expenses After Receiving the Customary and Necessary Substantiation, in Each Case, as of the Separation Date. (B) Exercise of Option Awards. Subject to Section 3 Below, All of Your Vested and Exercisable Options as of the Separation Date Shall Continue to Be Exercisable Until 5:00 Pm (Pacific Daylight Time) on June 30, 2016

from 8-K 12 pages Notice of Inducement Stock Option Grant

from 8-K 6 pages March 23, 2016 Scott Myers

from 10-K 7 pages Third Amendment to Patent License Agreement Between STC.UNM and Oncothyreon Inc

from 10-K 3 pages Oncothyreon Inc. Amendment No. 2 to Diana Hausman Offer Letter